Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1395-1404

  Monceau, Virginie ^a,b   Pasinetti, Nadia ^a,e   Schupp, Charlotte ^a   Pouzoulet, Fred ^a,d   Opolon, Paule ^a   Vozenin, Marie Catherine ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d INSTITUT CURIE   (France)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cardiac toxicity; Fibrosis; Pulmonary fibrosis; Radiation therapy; Rho ROCK; ROCK inhibition; Smad; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; PRAVASTATIN; RHO B KINASE; RHO KINASE; SIMVASTATIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; AMIDE; CTGF PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOSKELETON; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HEART FAILURE; HEART FUNCTION TEST; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IRRADIATION; LUNG FIBROSIS; LUNG INJURY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE STRUCTURE; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEART; HEART MUSCLE FIBROSIS; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION PNEUMONIA; THORAX;

AMIDES; ANIMALS; BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOSKELETON; ENDOMYOCARDIAL FIBROSIS; FEMALE; HEART; LUNG; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PRAVASTATIN; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RADIATION INJURIES; RADIATION PNEUMONITIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RHO-ASSOCIATED KINASES; RHOB GTP-BINDING PROTEIN; SIMVASTATIN; SMAD PROTEINS; THORAX;

EID: 79952547870     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011395     Document Type: Article

References (51)

1. Weichselbaum R. Radiation's outer limits. Nat Med 2005; 11: 477-8.
2. Hauer-Jensen M, Wang J, Denham JW. Bowel injury: current and evolving management strategies. Semin Radiat Oncol 2003; 13: 357-71.
3. Anscher MS. The irreversibility of radiation-induced fibrosis: fact or folklore? J Clin Oncol 2005; 23: 8551-2.
4. Bourgier C, Vozenin-Brotons MC, Arriagada R. Enhanced local control by radiation boost in breast cancer: back side of the coin? J Clin Oncol 2007; 25: 5841-3.
5. Haydont V, Riser BL, Aigueperse J, et al. Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF {beta}1. Am J Physiol 2008; 294: C1332-41.
6. Haydont V, Bourgier C, Pocard M, et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007; 13: 5331-40.
7. Wang J, Boerma M, Fu Q, et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol, Biol, Phys 2007; 68: 1483-90.
8. Haydont V, Gilliot O, Rivera S, et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol, Biol, Phys 2007; 68: 1471-82.
9. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001; 114: 2713-22.
10. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
11. Teichholz LE, Kreulen T, Herman MV, et al. Problems in echocardiographic volume determinations: echocardiographicangiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7-11.
12. Vozenin-Brotons MC, Milliat F, Sabourin JC, et al. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int J Radiat Oncol Biol Phys 2003; 56: 561-72.
13. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003; 160: 381-407.
14. Yamada M, Wong FL, Fujiwara S, et al. Noncancer disease incidence in atomic bomb survivors, 1958-1998. Radiat Res 2004; 161: 622-32.
15. Guldner L, Haddy N, Pein F, et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Radiother Oncol 2006; 81: 47-56.
16. Joiner MCE, Van der Kogel AE. Basic clinical radiobiology 4th edition. London, 2009.
17. Shimizu Y, Dobashi K, Iizuka K, et al. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med 2001; 163: 210-7.
18. Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 2005; 61: 842-50.
19. Schultz-Hector S. Heart. In: Scherer E, Streffer C, Trott K, Eds. Radiopathology of Organs and Tissues. Heidelberg Verlag, 1991. p.347.
20. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007; 67: 10-8.
21. Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Investig 2001; 107: 1395-402.
22. Anversa P, Leri A, Rota M, et al. Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells (Dayton, Ohio) 2007; 25: 589-601.
23. Boerma M, van der Wees CG, Vrieling H, et al. Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genom 2005; 6: 6.
24. Schneiders D, Heger J, Best P, et al. SMAD proteins are involved in apoptosis induction in ventricular cardiomyocytes. Cardiovasc Res 2005; 67: 87-96.
25. Wenzel S, Abdallah Y, Helmig S, et al. Contribution of PI 3-kinase isoforms to angiotensin II-and alpha-adrenoceptormediated signalling pathways in cardiomyocytes. Cardiovascular research 2006; 71: 352-62.
26. Nishida M, Tanabe S, Maruyama Y, et al. G alpha 12/13-and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 2005; 280: 18434-41.
27. Nishida M, Sato Y, Uemura A, et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J 2008; 27: 3104-15.
28. Parlakian A, Charvet C, Escoubet B, et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 2005; 112: 2930-9.
29. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNAmediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009; 105: 585-94.
30. Gomez GA, Park JJ, Panahon AM, et al. Heart size and function after radiation therapy to the mediastinum in patients with Hodgkin's disease. Cancer Treatment Reports 1983; 67: 1099-103.
31. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys 2008; 72: 170-7.
32. Bourgier C, Haydont V, Milliat F, et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005; 54: 336-43.
33. Haydont V, Mathe D, Bourgier C, et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005; 76: 219-25.
34. Brigstock DR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signaling 2010; 4:1-4.
35. Panek AN, Posch MG, Alenina N, et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 2009; 4: e6743.
36. Wu S, Platteau A, Chen S, et al. Conditional Over-expression of Connective Tissue Growth Factor Disrupts Postnatal Lung Development. Am J Respiratory Cell Mol Biol 2009; 42:552-63.
37. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446-56.
38. Vozenin-Brotons MC, Milliat F, Linard C, et al. Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res 2004; 161: 299-311.
39. Haydont V, Bourgier C, Vozenin-Brotons MC. Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol 2007; 80 Spec No 1: S32-40.
40. Kajimoto H, Hashimoto K, Bonnet SN, et al. Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation 2007; 115: 1777-88.
41. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-70.
42. Breitenlechner C, Gassel M, Hidaka H, et al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure (Camb) 2003; 11: 1595-607.
43. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular of physiology and pathophysiology. Circ Res 2006; 98: 322-34.
44. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol 2006; 290: C661-8.
45. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 2007; 292: H2598-606.
46. Williams JP, Hernady E, Johnston CJ, et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 2004; 161: 560-7.
47. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19: 709-18.
48. Zhang YM, Bo J, Taffet GE, et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 2006; 20: 916-25.
49. Liu A, Cerniglia GJ, Bernhard EJ, et al. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci USA 2001; 98: 6192-7.
50. Ader I, Toulas C, Dalenc F, et al. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 2002; 21: 5998-6006.
51. Milia J, Teyssier F, Dalenc F, et al. Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ 2005; 12: 492-501.